ProFibrix, with headquarters in Leiden, The Netherlands and a subsidiary in Seattle, WA, USA, focuses on the development and commercialization of a unique, innovative suite of bioactive products for the haemostasis and regenerative medicine markets. Lead product FibrocapsTM, a dry powder fibrin sealant to stop acute and severe bleeding, has recently completed a European Phase II trial in liver surgery. ProFibrix is preparing for a US and European Phase II trial in 2010 and a single pivotal Phase III trial in 2011. In the recombinant fibrinogen program industrial scale production has been achieved using a human cell line.

Web: www.profibrix.com/